Vitex Joining Red Blood Cell Viral Inactivation System Development Race
This article was originally published in The Gray Sheet
Executive SummaryAn invesitigation device exemption submission for Vitex' RBCC red blood cell viral inactivation system is expected in the second half of 1999, the Melville, New York-based company reports.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.